📊 ANIK Key Takeaways
Is Anika Therapeutics, Inc. (ANIK) a Good Investment?
Anika Therapeutics is a medtech company with a strong balance sheet but deteriorating operational performance. Declining revenue (-5.9% YoY), persistent operating losses (-18.5% margin), and negative free cash flow (-$6.3M) indicate fundamental business challenges despite solid liquidity and low leverage. The company must stabilize revenue and achieve profitability to justify investment.
Anika Therapeutics shows mixed fundamentals: a strong balance sheet, high liquidity, and positive free cash flow provide financial stability, but declining revenue and negative operating margins indicate the core business is not yet generating consistent profitable growth. The sharp improvement in net income is encouraging, but growth quality remains questionable until revenue stabilizes and operating leverage improves.
Anika Therapeutics, Inc. Key Strengths (ANIK)
- Strong balance sheet with low leverage (Debt/Equity: 0.19x) providing financial flexibility
- Excellent liquidity position (Current Ratio: 4.46x, Quick Ratio: 3.37x) with $41M cash reserves
- Healthy gross margins (64.2%) indicating competitive product positioning and pricing power
- Strong liquidity with a 4.72x current ratio and $57.48M in cash supports operational flexibility
- Low leverage with debt/equity of 0.17x limits balance-sheet risk
- Positive operating cash flow and free cash flow indicate the business is still generating cash despite accounting losses
ANIK Stock Risks: Anika Therapeutics, Inc. Investment Risks
- Declining revenue trend (-5.9% YoY) suggests loss of market share or demand weakness
- Significant operating losses (-$5.5M) and negative net margin (-17.1%) indicate operational inefficiency
- Negative operating cash flow (-$4.8M) and free cash flow (-$6.3M) showing cash burn despite adequate reserves
- Revenue declined 5.9% year over year, signaling weak top-line momentum
- Negative operating and net margins show the company has not restored sustainable profitability
- Returns on equity and assets remain negative, reflecting inefficient capital utilization
Key Metrics to Watch
- Revenue stabilization and return to growth
- Operating cash flow improvement toward positive territory
- Path to operating profitability and operating margin expansion
- Revenue growth recovery and product-level sales mix
- Operating margin and free cash flow consistency
Anika Therapeutics, Inc. (ANIK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.46x current ratio provides a solid financial cushion.
ANIK Profit Margin, ROE & Profitability Analysis
ANIK vs Healthcare Sector: How Anika Therapeutics, Inc. Compares
How Anika Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Anika Therapeutics, Inc. Stock Overvalued? ANIK Valuation Analysis 2026
Based on fundamental analysis, Anika Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Anika Therapeutics, Inc. Balance Sheet: ANIK Debt, Cash & Liquidity
ANIK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Anika Therapeutics, Inc.'s revenue has declined by 18% over the 5-year period, indicating business contraction. The most recent EPS of $-5.64 indicates the company is currently unprofitable.
ANIK Revenue Growth, EPS Growth & YoY Performance
ANIK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $26.2M | -$4.9M | $-0.34 |
| Q3 2025 | $27.8M | -$88.0K | $-0.16 |
| Q2 2025 | $28.2M | -$88.0K | $0.00 |
| Q1 2025 | $26.2M | -$4.5M | $-0.31 |
| Q3 2024 | $38.8M | -$88.0K | $-0.45 |
| Q2 2024 | $41.9M | -$88.0K | $-0.01 |
| Q1 2024 | $37.9M | -$4.5M | $-0.31 |
| Q3 2023 | $40.3M | -$2.7M | $-0.29 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Anika Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ANIK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Anika Therapeutics, Inc. (CIK: 0000898437)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ANIK
What is the AI rating for ANIK?
Anika Therapeutics, Inc. (ANIK) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ANIK's key strengths?
Claude: Strong balance sheet with low leverage (Debt/Equity: 0.19x) providing financial flexibility. Excellent liquidity position (Current Ratio: 4.46x, Quick Ratio: 3.37x) with $41M cash reserves. ChatGPT: Strong liquidity with a 4.72x current ratio and $57.48M in cash supports operational flexibility. Low leverage with debt/equity of 0.17x limits balance-sheet risk.
What are the risks of investing in ANIK?
Claude: Declining revenue trend (-5.9% YoY) suggests loss of market share or demand weakness. Significant operating losses (-$5.5M) and negative net margin (-17.1%) indicate operational inefficiency. ChatGPT: Revenue declined 5.9% year over year, signaling weak top-line momentum. Negative operating and net margins show the company has not restored sustainable profitability.
What is ANIK's revenue and growth?
Anika Therapeutics, Inc. reported revenue of $29.6M.
Does ANIK pay dividends?
Anika Therapeutics, Inc. does not currently pay dividends.
Where can I find ANIK SEC filings?
Official SEC filings for Anika Therapeutics, Inc. (CIK: 0000898437) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ANIK's EPS?
Anika Therapeutics, Inc. has a diluted EPS of $-0.37.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ANIK's fundamental grade?
Based on our AI fundamental analysis in June 2026, Anika Therapeutics, Inc. has a C grade with 76% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ANIK stock overvalued or undervalued?
Valuation metrics for ANIK: ROE of -3.8% (sector avg: 15%), net margin of -17.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ANIK's AI grade for 2026?
Our dual AI analysis gives Anika Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ANIK's free cash flow?
Anika Therapeutics, Inc.'s operating cash flow is $-4.8M, with capital expenditures of $1.4M. FCF margin is -21.2%.
How does ANIK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -17.1% (avg: 12%), ROE -3.8% (avg: 15%), current ratio 4.46 (avg: 2).